TrialBlood advances2023

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.

Emmanuel Bachy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.